CREDIT AGREEMENT Dated as of May 17, 2017, among ASHLAND LLC, as the Borrower, THE BANK OF NOVA SCOTIA, as Administrative Agent, Swing Line Lender and an L/C Issuer, CITIBANK, N.A., as Syndication Agent, The Other Lenders and L/C Issuers Party Hereto,...Credit Agreement • May 18th, 2017 • Ashland Global Holdings Inc • Wholesale-chemicals & allied products • New York
Contract Type FiledMay 18th, 2017 Company Industry JurisdictionThis CREDIT AGREEMENT (this “Agreement”) is entered into as of May 17, 2017, among ASHLAND LLC, a Kentucky limited liability company (formerly known as Ashland Inc.) (“Ashland”), each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), THE BANK OF NOVA SCOTIA, as Administrative Agent, Swing Line Lender and an L/C Issuer, each other L/C Issuer from time to time party hereto and CITIBANK, N.A., as Syndication Agent.
STOCK PURCHASE AGREEMENT Dated as of April 14, 2017 by and amongStock Purchase Agreement • May 18th, 2017 • Ashland Global Holdings Inc • Wholesale-chemicals & allied products • Delaware
Contract Type FiledMay 18th, 2017 Company Industry JurisdictionTHIS STOCK PURCHASE AGREEMENT, dated as of April 14, 2017 (this “Agreement”), is made by and among: (i) Ashland LLC, a Kentucky limited liability company (“Parent”); (ii) Pharmachem Laboratories, Inc., a New Jersey corporation (the “Company”); (iii) the holders of Common Stock identified on Exhibit A hereto (the “Company Shareholders”); (iv) Dr. David Peele (the “Atom Minority Shareholder”); and (v) Photon SH Representative LLC, solely in its capacity as the shareholder representative hereunder (the “Shareholders’ Representative”). Capitalized terms used herein without definition shall have the meanings specified in ARTICLE 1.
AMENDMENT NO. 1 TO THE STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 18th, 2017 • Ashland Global Holdings Inc • Wholesale-chemicals & allied products
Contract Type FiledMay 18th, 2017 Company IndustryThis Amendment, dated as of May 16, 2017 (this “Amendment”), amends the Stock Purchase Agreement, dated as of April 14, 2017 (the “Purchase Agreement”), by and among Ashland LLC, a Kentucky limited liability company (“Parent”); Pharmachem Laboratories, Inc., a New Jersey corporation (the “Company”); the holders of Common Stock identified on Exhibit A of the Purchase Agreement (the “Company Shareholders”); Dr. David Peele (the “Atom Minority Shareholder”); and Photon SH Representative LLC, solely in its capacity as the shareholder representative thereunder (the “Shareholders Representative”). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings as set forth to them in the Purchase Agreement.